Opiant Pharmaceuticals
Pharmaceutical company; develops medicines for the treatment of addictions and overdose
Based in CA
AI Overview
With $940K in lobbying spend across 18 quarterly filings, Opiant Pharmaceuticals is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2019 to 2023.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $0 |
| 2020 | $250K |
| 2021 | $330K |
| 2022 | $260K |
| 2023 | $100K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Opiant Pharmaceuticals disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Health Issues
Issues related to opioid addiction
Opioid epidemic, drug overdose, and national security threat posed by Fentanyl
Opioid epidemic, Fentanyl crisis,and Cannabinoid Overdose
Opioids/FDA
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.